A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.
← catalyst calendarSponsored by Enanta Pharmaceuticals, Inc (industry) · ENTA — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
187actual
Sites
84
Countries
Argentina, Bulgaria, Colombia +9
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-11-29 | actual | When the study began enrolling |
| Primary completion | 2025-06-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-23 | actual | The whole study's end, after follow-up |
| First posted | 2022-10-06 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-19 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-19 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- RSV Infection
Interventions
- Drug: EDP-938
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime to Resolution of RSV Lower Respiratory Tract Disease (LRTD) Symptoms
measured Day 1 through Day 33
Time to Complete Resolution of LRTD Symptoms for the mITT Population
measured Day 1 through Day 33
Time to Complete Resolution of LRTD Symptoms for the HR3 Population
measured Day 1 through Day 33
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2023-10-30 · 1.4 MB · Prot_000.pdf
Statistical Analysis Planposted 2025-06-06 · 2.0 MB · SAP_001.pdf
Permalink · ENTA's whole pipeline · Catalyst calendar · Every registered study · What changed